These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 27888904)
1. [Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases]. López-Miranda J; Pintó X Clin Investig Arterioscler; 2016 May; 28 Suppl 2():31-38. PubMed ID: 27888904 [TBL] [Abstract][Full Text] [Related]
2. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
9. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
10. [Lipid control in high-risk patients: focus on PCSK9 inhibitors]. Filardi PP; Paolillo S; Trimarco B G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease]. Christiansen MK; Jensen HK Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 antibodies: A new class of lipid-lowering drugs. Gouni-Berthold I Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300 [TBL] [Abstract][Full Text] [Related]
13. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
14. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors? Bittner V Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023 [No Abstract] [Full Text] [Related]
15. Update of Clinical Trials of Anti-PCSK9 Antibodies. Wu NQ; Li S; Li JJ Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406 [TBL] [Abstract][Full Text] [Related]
17. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
19. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy. Yoon CH; Watson K Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646 [TBL] [Abstract][Full Text] [Related]
20. Do PCSK9 inhibitors reduce cardiovascular events? Kolber MR; Nickonchuk T; Turgeon R Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099 [No Abstract] [Full Text] [Related] [Next] [New Search]